"Bringing these results to AAN reflects the significant momentum behind Deramiocel and our deep commitment to the Duchenne community," said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. "The HOPE-3 data tell a compelling story of preserved function, slowed decline, and real-world impact on patients' daily lives, evidence we believe positions Deramiocel as a potentially transformative therapy for Duchenne. With our BLA currently under FDA review and a PDUFA target action date of August 22, 2026, ...